Serum talin-1 is a potential novel biomarker for diagnosis of hepatocellular carcinoma in Egyptian patients

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 6, 2013, Pages 3819-3823

  Youns, Mahmoud M ^a   Abdel Wahab, Abdel Hady A ^b   Hassan, Zeinab A ^a   Attia, Mohamed S ^a  

^a Helwan   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Alpha fetoprotein; Hepatocellular carcinoma; Liver cirrhosis; Marker; Talin 1

Indexed keywords

EID: 84882671504     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.6.3819     Document Type: Article

References (31)

1. Abdel-Aziz F, Habib M, Mohamed MK, et al (2000). Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology, 32, 111-5.
2. Altekruse S, McGlynn K Reichman M (2009). Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol, 27,1485-91.
3. Attallah AM, El-Far M, Abdel Malak C, et al (2011). Evaluation of cytokeratin-1 in the diagnosis of hepatocellular carcinoma. Clinica Chimica Acta, 412, 2310-5.
4. Bessa S, Elwan N, Suliman G, El-Shourbagy S (2010). Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. Arch Med Res, 41, 541-7.
5. Bruix J and Sherman M (2005). Management of hepatocellular carcinoma. Hepatology, 42, 1208-36.
6. Critchley DR, Talin In Kreis T, Vale R (1999). Guidebook to the extracellular matrix, anchor, and adhesion proteins. Oxford University Press, pp. 82-85, Oxford.
7. El-Serag HB (2004). Hepatocellular carcinoma: recent trends in the United States. Gastroenterology, 127, 27-34.
8. El-Serag HB, Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-76.
9. El-Zayadi AR, Badran HM, Barakat EM, et al (2005). Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol, 11, 5193-8.
10. Ferlay J, Bray F, Pisani P (2004). GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Press; Lyon: 2004. IARC CancerBase No. 5. version 2.0.
11. Freedman L, Edwards B, Ries L (2006). Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the middle east cancer consortium (MECC) compared with US SEER. National Cancer Institute. Bethesda, MD: NIH Pub. No. 06-5873.
12. Hassan MM, Zaghloul AS, El-Serag HB (2001). The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J Clin Gastroenterol, 33, 123-6.
13. Horwitz A, Duggan K, Buck C, et al (1986). Interaction of plasma-membrane ?bronectin receptor with talin - a transmembrane linkage. Nature, 320, 531-3.
14. Kanamori H, Kawakami T, Effendi K, et al (2011). Identification by differential tissue proteome analysis of Talin-1 as a novel molecular marker of progression of hepatocellular carcinoma. Oncology, 80, 406-15.
15. Khattab MA, Eslam M, Sharwae MA (2010). Seroprevalence of hepatitis C and B among blood donors in Egypt: Minya Governorate, 2000-2008. Am J Infect Control, 38, 640-1.
16. Liotta LA, Kohn E (2004). Anoikis: cancer and the homeless cell. Nature, 430, 973-4.
17. Makuuchi M, Kokudo N, Arii S, et al (2008). Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res, 38, 37-51.
18. Mendy M, Walton R (2009). Molecular pathogenesis and early detection of hepatocellular carcinoma-perspectives from West Africa. Cancer Lett, 286, 44-51.
19. Mizejewski GJ (1999). Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med, 222, 124-38.
20. Parkin D, Bray F, Ferlay J, Pisani P (2001). Estimating the world cancer burden: Globocan 2000. Int J Cancer, 94, 153-6.
21. Parkin D, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
22. Sakamoto S, McCann RO, Dhir R, Kyprianou N (2010). Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res, 70, 1885-95.
23. Senetar M, Moncman C, McCann R (2007). Talin2 is induced during striated muscle differentiation and istargeted to stable adhesion complexes in mature muscle. Cell Motil Cytoskeleton, 64, 157-73.
24. Senetar MA, McCann RO (2005). Gene duplication and functional divergence during evolution of the cytoskeletal linker protein talin. Gene, 362, 141-52.
25. Slater M, Cooper M, Murphy CR (2007). The cytoskeletal proteins alpha-actinin, Ezrin, and talin are De-expressed in endometriosis and endometrioid carcinoma compared with normal uterine epithelium. Appl Immunohistochem Mol Morphol, 15, 170-4.
26. Tadokoro S, Shattil SJ, Eto K, et al (2003). Talin binding to integrin beta tails:a final common step in integrin activation. Science, 302, 103-6.
27. Teofanescu I, Gologan E, Stefanescu E, Balan G (2010). Surveillance of cirrhosis for hepatocellular carcinoma- -clinical validation of new serological biomarkers for improved diagnosis. Rev Med Chir Soc Med Nat Iasi, 114, 39-46.
28. Thomas M, Zhu A (2005). Hepatocellular carcinoma: the need for progress. J Clin Oncol, 23, 2892-9.
29. Tsujioka M, Yoshida K, Inouye K (2004). Talin B is required for force transmission in morphogenesis of dictyostelium. EMBO J, 23, 2216-25.
30. Zhang JL, Qian YB, Zhu LX, Xiong QR (2011). Talin1, a valuable marker for diagnosis and prognostic assessment of human hepatocelluar carcinomas. Asian Pac J Cancer Prev, 12, 3265-9.
31. Zhang X, Jiang G, Cai Y, et al (2008). Talin depletion reveals independence of initial cell spreading from integrin activation and traction. Nat Cell Biol, 10, 1062-8.